ISRCTN73459064Active, not recruitingUnknown
Single centre drug-drug interaction study with levothyroxine and zinc-D-gluconate in healthy subjects
niversity Hospital of Zurich0 sites15 target enrollmentStarted: August 14, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Age 18-65 years old
- •2. Informed Consent as documented by signature
Exclusion Criteria
- •1. Contraindications to the drugs under study, e.g. known hypersensitivity or allergy
- •2. Need for any kind of oral drug therapy (including oral contraceptive or nutritional supplements) for the duration of the study, except for the symptomatic treatment of common conditions like headache, musculoskeletal pain, common cold, gastritis, nausea and diarrhoea with medication containing paracetamol, non-steroidal anti-inflammatory drugs, meclizine, domperidone, and loperamide, as long they are taken on an as-per-need basis and not 72 hours before a visit.
- •3. Planned intake of oral calcium, magnesium, zinc or iron supplements for the duration of the study
- •4. Other clinically significant concomitant disease states (e.g., renal failure, thyroid dysfunction, cardiovascular disease, arterial hypertension, any other medical condition that could lead to an albumin deficiency such as anorexia etc.)
- •5. Abnormal findings in the screening tests (laboratory, ECG, physical examination).
- •6. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
- •7. Participation in another study with an investigational drug within the 30 days preceding and during the present study
- •8. Previous enrolment into the current study
- •9. Enrolment of the investigator, his/her family members, employees and other dependent persons
- •Applicable only to female participants:
- •1. Women who are pregnant or breastfeeding
- •2. Intention to become pregnant during the study
- •3. Lack of safe contraception, defined as female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception (defined as sexual abstinence with men (except in case of medically proven male sterility of the male sexual partner), use of a condom, use of an intrauterine device (contraceptive coil with or without hormones), use of a dermal or subcutaneous device or a subcutaneous injection with hormones (such as Evra® or Implanon®), use of a vaginal hormonal device (such as NuvaRing®)) for the entire study duration. Female participants who are surgically sterilised / hysterectomized or post-menopausal for longer than 2 years are not considered as being of childbearing potential.
Investigators
Similar Trials
Active, not recruiting
Phase 4
Drug interaction study with thyroid hormone and magnesium preparation in healthy volunteersHypothyroidismNutritional, Metabolic, EndocrineISRCTN18075783niversity Hospital of Zurich12
Completed
Not Applicable
A One-Way Drug-Drug Interaction Study to Assess the Effect of Ritonavir-boosted Atazanavir on the Pharmacokinetics, Safety and Tolerability of BMS-790052 in Healthy Subjectsviral liver inflammation10047438Hepatitis CNL-OMON36726Bristol-Myers Squibb14
Completed
Not Applicable
A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTSviral liver inflammation10047438Hepatitis CNL-OMON36747Bristol-Myers Squibb17
Not yet recruiting
Phase 1
A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy VolunteersACTRN12624001072505ura Bio18
Completed
Phase 1
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4ISRCTN93845260Helsinn Healthcare SA24